Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- Streptococcus agalactiae
- Clinical manifestations
- Risk factors
- Virulence factors
- Prevention strategies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Fouch, S. (2024, October 31). Streptococcus agalactiae [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 19, 2024, from https://doi.org/10.69645/CNIP4704.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Sarah Fouch has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Introduction to Microbes
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, everyone. My name
is Dr. Sarah Fouch.
Welcome to this short
recording where we
will be considering
group B streptococci.
We will think about the
clinical conditions that
this organism is associated
with, and we will
also think about the
virulence factors that help
this organism to be
associated with the
clinical conditions.
0:26
Let's think about
group B streptococci,
and these are gram
positive cocci.
We will isolate
them on blood agar
because they require a
nutritionally rich media,
and when they grow,
they will appear as
buttery-like colonies.
When we compare the
haemolysis patterns
between group A and
group B streptococci,
both of these organisms produce
beta-haemolysis so we will
have complete haemolysis
of the red blood cells.
But group A
streptococci will have
quite a large zone
of haemolysis.
In comparison, group B has
quite a small zone
of beta-haemolysis.
We are able to type group B
streptococci and we will use
the group-specific antigens
that are expressed
on the cell wall.
Again, we can do this
through grouping
agglutination investigations.
There are 10 serotypes of
group B streptococci based
on their capsular
polysaccharides.
But the interesting thing about
group B streptococci is
although it has a range
of virulence factors,
it doesn't tend to cause
as many infections in comparison
to group A streptococci.
When we think about the enzymes
that this organism can produce,
we can use various enzymes
for identification.
But again, the group
B streptococci
does not tend to
use the enzymes for
pathogenesis because
we do not see
many of these in quite
nasty infections.
When we think about
group B streptococci,
as with other organisms,
there are areas of
the body where we
will find this as normal flora.
We tend to find group B
streptococci colonising
our lower
gastrointestinal system
and also our genital
urinary system.